TITLE

PRANA EXPANDS COLLABORATION WITH UNIVERSITY OF MELBOURNE

PUB. DATE
May 2003
SOURCE
Worldwide Biotech;May2003, Vol. 15 Issue 5, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces that Melbourne, Australia-based Prana Biotechnology Ltd. will expand its existing University of Melbourne agreement to lengthen the collaboration by two years to 2006 while intensifying research into new drug candidates.
ACCESSION #
9666435

 

Related Articles

  • Corrections & Clarifications.  // BioWorld Today;7/15/2009, Vol. 20 Issue 134, p2 

    A correction to an article on the Phase II data from Prana Biotechnology Ltd. is presented.

  • PRANA COMPLETES CLINICAL PHASE OF ALZHEIMER'S DRUG TRIAL.  // Worldwide Biotech;Mar2002, Vol. 14 Issue 3, p3 

    Reports on the completion of the clinical trial for drugs against Alzheimer's disease by Prana Biotechnology Ltd.

  • Financings Roundup. Boggs, Jennifer // BioWorld Today;7/15/2011, Vol. 22 Issue 136, p4 

    The article reports on the decision of Prana Biotechnology Ltd. of Melbourne, Victoria to file a prospectus supplement to sell shares through an at-the-market offering.

  • Company SnapShot.  // Acquisdata Company SnapShot: Prana Biotechnology Limited;9/7/2015, p1 

    The article presents a company report of Prana Biotechnology Ltd. and discusses topics such as the firm's financial announcement, company profile, and overview of its competitors such as Acrux Ltd., Agenic Ltd. and Avexa Ltd.

  • Clinic Roundup.  // BioWorld Today;9/16/2013, Vol. 24 Issue 177, p10 

    This section offers news briefs on biotechnology clinics including a report on the Phase II trial testing of PBT2 from Prana Biotechnology Ltd., and the presentation for the evaluation of the drug Amitiza from Sucampo AG in chronic idiopathic constipation at the Swiss Society of Gastroenterology.

  • Prana Biotechnology Upgrades to Level II. Platt, Gordon // Global Finance;Nov2002, Vol. 16 Issue 11, p22 

    Highlights Melbourne, Victoria-based Prana Biotechnology's upgrading of its Level 1 American depositary receipt program to a Nasdaq-listed Level II program. Impact of the nasdaq listing on the company.

  • Hot company. Quinlivan, Beth // BRW;3/28/2002, Vol. 24 Issue 12, p18 

    Features the success of Prana Biotechnogy Ltd. on the biotechnology industry in Australia. Increase in the share prices of the company; Popularity of the business for the research conducted on Alzheimer's disease; Approval of the U.S. Food and Drug Administration on the human trials of the drug...

  • Financings Roundup.  // BioWorld Today;9/13/2007, Vol. 18 Issue 178, p3 

    The article reports that Australian firm Prana Biotechnology Ltd. has raised funds to support ongoing development of the company's lead compound PBT2, which is in a Phase IIa trial in Alzheimer's disease patients. The company raised A$7 million through a private placement of about 24.6 million...

  • Prana Shares Soar on PBT2's Positive Data.  // Bioworld Week;3/3/2008, Vol. 16 Issue 9, p4 

    The article reports on the developments of Melbourne, Australia-based Prana Biotechnology Ltd. According to the article, the company's shares increases when the result of the Phase IIa study proved that its experimental Alzheimer's disease compound PBT2 was safe and tolerable. It reveals that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics